Liv-52 Attenuates Erlotinib-Induced Liver Injury via Modulation of Oxidative Stress, Inflammation, and Apoptosis in Rats
Özet
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is widely used in cancer therapy; however, hepatotoxicity limits its clinical use. This study investigated the protective effects of Liv-52, a polyherbal hepatoprotective formulation, against erlotinib-induced hepatotoxicity in rats and compared its efficacy with melatonin. The animals (n = 24, Wistar albino rats) were randomly categorized into four groups: healthy (HG), erlotinib (ERG), Liv-52 + erlotinib (LEG), and melatonin + erlotinib (MEG). Liv-52 (50 mg/kg/day, orally) and melatonin (10 mg/kg/day, orally) were administered once daily for two weeks. Erlotinib (10 mg/kg, orally) was given every other day to ERG, LEG, and MEG groups for two weeks. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) were measured. Hepatic malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) levels were analyzed. Additionally, double immunofluorescence staining was performed to evaluate apoptotic (poly[ADP-ribose] polymerase-1 [PARP-1], apoptosis-inducing factor [AIF]), inflammatory (cyclooxygenase-2 [COX-2]), and anti-inflammatory (interleukin-10 [IL-10]) biomarkers in liver tissues. Histopathological examination was also conducted to assess structural alterations. Erlotinib significantly increased MDA, ALT, AST, and LDH while decreasing tGSH, SOD, and CAT (p < 0.001). Strong immunoreactivity for PARP-1, AIF, IL-10, and COX-2, as well as severe hydropic degeneration and necrosis, was observed in ERG (p < 0.05). Both Liv-52 and melatonin significantly ameliorated biochemical, histopathological, apoptotic, and inflammatory alterations (p < 0.05). Notably, Liv-52 demonstrated superior hepatoprotective efficacy compared to melatonin. These findings indicate that Liv-52 effectively attenuates erlotinib-induced hepatotoxicity by modulating oxidative stress, inflammatory responses, and apoptotic pathways, thereby preserving liver function and structural integrity. © 2026 by the authors.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Bulut, Seval | |
| dc.contributor.author | Altuner, Durdu | |
| dc.contributor.author | Suleyman, Bahadir | |
| dc.contributor.author | Mammadov, Renad | |
| dc.contributor.author | Ozkaraca, Mustafa | |
| dc.contributor.author | Gungor, Ali | |
| dc.contributor.author | Kuzucu, Mehmet | |
| dc.contributor.author | Hendem, Engin | |
| dc.contributor.author | Suleyman, Halis | |
| dc.date.accessioned | 2026-10-18T20:25:41.590622548Z | |
| dc.date.available | 2026-10-18T20:25:41.590622548Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is widely used in cancer therapy; however, hepatotoxicity limits its clinical use. This study investigated the protective effects of Liv-52, a polyherbal hepatoprotective formulation, against erlotinib-induced hepatotoxicity in rats and compared its efficacy with melatonin. The animals (n = 24, Wistar albino rats) were randomly categorized into four groups: healthy (HG), erlotinib (ERG), Liv-52 + erlotinib (LEG), and melatonin + erlotinib (MEG). Liv-52 (50 mg/kg/day, orally) and melatonin (10 mg/kg/day, orally) were administered once daily for two weeks. Erlotinib (10 mg/kg, orally) was given every other day to ERG, LEG, and MEG groups for two weeks. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) were measured. Hepatic malondialdehyde (MDA), total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) levels were analyzed. Additionally, double immunofluorescence staining was performed to evaluate apoptotic (poly[ADP-ribose] polymerase-1 [PARP-1], apoptosis-inducing factor [AIF]), inflammatory (cyclooxygenase-2 [COX-2]), and anti-inflammatory (interleukin-10 [IL-10]) biomarkers in liver tissues. Histopathological examination was also conducted to assess structural alterations. Erlotinib significantly increased MDA, ALT, AST, and LDH while decreasing tGSH, SOD, and CAT (p < 0.001). Strong immunoreactivity for PARP-1, AIF, IL-10, and COX-2, as well as severe hydropic degeneration and necrosis, was observed in ERG (p < 0.05). Both Liv-52 and melatonin significantly ameliorated biochemical, histopathological, apoptotic, and inflammatory alterations (p < 0.05). Notably, Liv-52 demonstrated superior hepatoprotective efficacy compared to melatonin. These findings indicate that Liv-52 effectively attenuates erlotinib-induced hepatotoxicity by modulating oxidative stress, inflammatory responses, and apoptotic pathways, thereby preserving liver function and structural integrity. © 2026 by the authors. | |
| dc.identifier.doi | 10.3390/ijms27093817 | |
| dc.identifier.eissn | 1422-0067 | |
| dc.identifier.issn | 1661-6596 | |
| dc.identifier.issue | 9 | |
| dc.identifier.pmcid | PMC13163866 | |
| dc.identifier.pmid | 42123402 | |
| dc.identifier.scopus | 2-s2.0-105038439759 | |
| dc.identifier.startpage | 3817 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/10481 | |
| dc.identifier.volume | 27 | |
| dc.identifier.wos | WOS:001763625600001 | |
| dc.language.iso | en | |
| dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
| dc.relation.ispartof | International Journal of Molecular Sciences | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | antioxidant | |
| dc.subject | apoptosis | |
| dc.subject | erlotinib | |
| dc.subject | inflammation | |
| dc.subject | Liv-52 | |
| dc.subject | melatonin | |
| dc.subject | Animals | |
| dc.subject | Antioxidants | |
| dc.subject | Chemical and Drug Induced Liver Injury | |
| dc.subject | Erlotinib Hydrochloride | |
| dc.subject | Liver | |
| dc.subject | Male | |
| dc.subject | Oxidative Stress | |
| dc.subject | Plant Extracts | |
| dc.subject | Rats | |
| dc.subject | Rats, Wistar | |
| dc.subject | alanine aminotransferase | |
| dc.subject | apoptosis inducing factor | |
| dc.subject | aspartate aminotransferase | |
| dc.subject | catalase | |
| dc.subject | cyclooxygenase 2 | |
| dc.subject | glutathione | |
| dc.subject | interleukin 10 | |
| dc.subject | lactate dehydrogenase | |
| dc.subject | liv 52 | |
| dc.subject | malonaldehyde | |
| dc.subject | nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase 1 | |
| dc.subject | superoxide dismutase | |
| dc.subject | plant extract | |
| dc.subject | alanine aminotransferase blood level | |
| dc.title | Liv-52 Attenuates Erlotinib-Induced Liver Injury via Modulation of Oxidative Stress, Inflammation, and Apoptosis in Rats | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 0 | |
| rdl.citation.wos | 0 | |
| rdl.department | Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | Department of Molecular Biology, Faculty of Arts and Sciences, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | Department of Medical Oncology, Mengucek Gazi Education and Research Hospital, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey. | |
| rdl.oa.status | gold | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
